ANNUAL REPORT FY23 53 14. Subsidiaries 2023 ownership interest 2022 ownership interest Nyrada Pty Ltd 100% 100% Norbio No.2 Pty Ltd 100% 100% Cardio Therapeutics Pty Ltd 100% 100% 15. Events after reporting period No matters or circumstances have arisen since 30 June 2023 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years. 16. Cash flow information Reconciliation of loss after income tax to net cash used in operating activities 2023 2022 $ $ Loss after income tax expense for the year (7,781,692) (3,959,661) Adjustments for: Depreciation & amortisation 6,534 4,734 Share-based payments 541,214 966,951 Change in operating assets and liabilities Decrease/(increase) in trade and other receivables (264,140) 207,096 Increase/(decrease) in trade and other payables 245,433 (197,978) Increase/(decrease) in employee benefits 53,260 55,170 (7,199,391) (2,923,688) Reconciliation of Cash Cash at the end of financial year as included in the statement of cash flows is reconciled to the related items in the statement of financial position as follows: 2023 2022 $ $ Cheque account 196,729 421,940 USD account 671 2,450,841 Saving bonus 3,511,361 7,943,258 3,708,761 10,816,039
RkJQdWJsaXNoZXIy MjE2NDg3